Martin Kenny

Martin Kenny

Auto-generated profile, based on publicly available information

Martin Kenny

Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
SDSukhraj Pal Singh Dhami
Sukhraj Pal Singh Dhami
SPSean Patmore
Sean Patmore
CCClaire Comerford
Claire Comerford
CBCiara M. Byrne
Ciara M. Byrne
BCBrenton Cavanagh
Brenton Cavanagh
JOJamie M. O'SUllivan
Jamie M. O'SUllivan
Breast cancer results in a three‐ to four‐fold increased risk of venous thromboembolism (VTE), which is associated with reduced patient survival. Despite this, the mechanisms underpinning breast cancer‐associated thrombosis remain poorly defined. Tumor cells can trigger endothelial cell (EC) activation resulting in increased von Willebrand factor (VWF) secretion. Importantly, elevated plasma VWF levels constitute an independent biomarker for VTE risk. Moreover, in a model of melanoma, treatment with low molecular weight heparin (LMWH) negatively regulated VWF secretion and attenuated tumor metastasis. To investigate the role of VWF in breast cancer metastasis and examine the effect of LMWH in modulating EC activation and breast tumor transmigration. von Willebrand factor levels were measured by ELISA. Primary ECs were used to assess tumor‐induced activation, angiogenesis, tumor adhesion, and transendothelial migration. Patients with metastatic breast cancer have markedly elevated plasma VWF:Ag levels that also correlate with poorer survival. MDA‐MB‐231 and MCF‐7 breast cancer cells induce secretion of VWF, angiopoietin‐2, and osteoprotegerin from ECs, which is further enhanced by the presence of platelets. Vascular endothelial growth factor‐A (VEGF‐A) plays an important role in modulating breast cancer‐induced VWF release. Moreover, VEGF‐A from breast tumor cells also contributes to a pro‐angiogenic effect on ECs. VWF multimers secreted from ECs, in response to tumor‐VEGF‐A, mediate adhesion of breast tumor cells along the endothelium. LMWH inhibits VWF‐breast tumor adhesion and transendothelial migration. Our findings highlight the significant crosstalk between tumor cells and the endothelium including increased VWF secretion which may contribute to tumor metastasis.

20 May 2022 in Science Advances
Verified
Journal Article
Open access
JBJuliane Baumann
Juliane Baumann
LSLaura Sachs
Laura Sachs
OOOliver Otto
Oliver Otto
ISIngmar Schoen
Ingmar Schoen
PNPeter Nestler
Peter Nestler
MBMarkus Bender
Markus Bender
MYH9 -related disease patients with mutations in the contractile protein nonmuscle myosin heavy chain IIA display, among others, macrothrombocytopenia and a mild-to-moderate bleeding tendency. In this study, we used three mouse lines, each with one point mutation in the Myh9 gene at positions 702, 1424, or 1841, to investigate mechanisms underlying the increased bleeding risk. Agonist-induced activation of Myh9 mutant platelets was comparable to controls. However, myosin light chain phosphorylation after activation was reduced in mutant platelets, which displayed altered biophysical characteristics and generated lower adhesion, interaction, and traction forces. Treatment with tranexamic acid restored clot retraction in the presence of tPA and reduced bleeding. We verified our findings from the mutant mice with platelets from patients with the respective mutation. These data suggest that reduced platelet forces lead to an increased bleeding tendency in patients with MYH9 -related disease, and treatment with tranexamic acid can improve the hemostatic function.

11 March 2022 in Science Advances
Verified
Journal Article
Open access
SLSebastian Lickert
Sebastian Lickert
MKMartin Kenny
Martin Kenny
KSKateryna Selcuk
Kateryna Selcuk
JMJohanna L. Mehl
Johanna L. Mehl
MBMarkus Bender
Markus Bender
VVViola Vogel
Viola Vogel
Platelets interact with multiple adhesion proteins during thrombogenesis, yet little is known about their ability to assemble fibronectin matrix. In vitro three-dimensional superresolution microscopy complemented by biophysical and biochemical methods revealed fundamental insights into how platelet contractility drives fibronectin fibrillogenesis. Platelets adhering to thrombus proteins (fibronectin and fibrin) versus basement membrane components (laminin and collagen IV) pull fibronectin fibrils along their apical membrane versus underneath their basal membrane, respectively. In contrast to other cell types, platelets assemble fibronectin nanofibrils using αIIbβ3 rather than α5β1 integrins. Apical fibrillogenesis correlated with a stronger activation of integrin-linked kinase, higher platelet traction forces, and a larger tension in fibrillar-like adhesions compared to basal fibrillogenesis. Our findings have potential implications for how mechanical thrombus integrity might be maintained during remodeling and vascular repair.

18 May 2022 in Advanced Healthcare Materials
Verified
Journal Article
Open access
MKMartin Kenny
Martin Kenny
SSStephani Stamboroski
Stephani Stamboroski
RTReem Taher
Reem Taher
DBDorothea Brüggemann
Dorothea Brüggemann
ISIngmar Schoen
Ingmar Schoen
The initial contact with blood and its components, including plasma proteins and platelets, directs the body's response to foreign materials. Natural scaffolds of extracellular matrix or fibrin contain fibrils with nanoscale dimensions, but how platelets specifically respond to the topography and architecture of fibrous materials is still incompletely understood. Here, planar and nanofiber scaffolds are fabricated from native fibrinogen to characterize the morphology of adherent platelets and activation markers for phosphatidylserine exposure and α‐granule secretion by confocal fluorescence microscopy and scanning electron microscopy. Different fibrinogen topographies equally support the spreading and α‐granule secretion of washed platelets. In contrast, preincubation of the scaffolds with plasma diminishes platelet spreading on planar fibrinogen surfaces but not on nanofibers. The data show that the enhanced interactions of platelets with nanofibers result from a higher locally accessible surface area, effectively increasing the ligand density for integrin‐mediated responses. Overall, fibrinogen nanofibers direct platelets toward robust adhesion formation and α‐granule secretion while minimizing their procoagulant activity. Similar results on fibrinogen‐coated polydimethylsiloxane substrates with micrometer‐sized 3D features suggest that surface topography could be used more generally to steer blood‐materials interactions on different length scales for enhancing the initial wound healing steps.

25 May 2020 in Platelets
Verified
Journal Article
Closed access
MKMartin Kenny
Martin Kenny
ISIngmar Schoen
Ingmar Schoen
Deep vein thrombosis (DVT) describes the clogging of veins in extremities, leading to pain, swelling, and potentially life-threatening pulmonary embolism. Although several known factors can provoke...

17 January 2018 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
CKClaire Kennedy
Claire Kennedy
LWLimy Wong
Limy Wong
DSDonal J Sexton
Donal J Sexton
JCJonathan Cowman
Jonathan Cowman
IOIrene Oglesby
Irene Oglesby
DKDermot Kenny
Dermot Kenny
Uraemic platelet dysfunction is not completely understood, in part due to non-physiological platelet function assays. We have developed a physiological flow-based assay that quantifies platelet function in microlitre volumes of blood under arterial shear. The aim of this study was to characterize platelet function before and after kidney transplantation. Ten patients scheduled for living donor kidney transplant surgery and nine healthy controls were analysed using the assay. The motional parameters of platelet behaviour on von Willebrand factor (VWF) were recorded using customized platelet tracking software. The assay was repeated 3–8 weeks post-transplant in the transplant group and at an interval of >3 weeks in normal healthy volunteers. Platelet–VWF interactions were markedly reduced in the 10 pre-transplant patients compared with the healthy controls. In seven patients with immediate graft function, dynamic platelet function returned to normal (despite a small decrease in haemoglobin and haematocrit), but remained markedly abnormal in the three patients with delayed graft function (DGF). Dynamic platelet function returned to normal following transplantation in those with immediate graft function. This early improvement was not observed in those with DGF. There may be important clinical implications, as patients with DGF are more likely to undergo invasive procedures, including transplant biopsies and insertion of central venous catheters.